Characteristics of 183 children with newly diagnosed AML
| AML . | All patients . | Assay, unsuccessful . | Assay, successful . | P . |
|---|---|---|---|---|
| Patients, no. | 183 | 55 | 128 | |
| Age, median (P25-P75), y | 6.9 (2.4-11.8) | 5.0 (1.8-10.3) | 7.5 (3.1-12.6) | .02 |
| WBC count, median (P25-P75), ×109/L | 23.5 (6.9-72.9) | 8.7 (3.8-39.2) | 28.3 (12.5-88.4) | < .001 |
| Sex, % M:F ratio | 55.2:44.8 | 56.4:43.6 | 54.6:45.4 | .83 |
| FAB distribution, no. (%) | < .001 | |||
| M0 | 8 (4.4) | 2 (3.6) | 6 (4.7) | |
| M1 | 22 (12.0) | 8 (14.5) | 14 (10.9) | |
| M2 | 43 (23.5) | 12 (21.8) | 31 (24.2) | |
| M3 | 7 (3.8) | 0 (0) | 7 (5.5) | |
| M4 | 47 (25.7) | 8 (14.5) | 39 (30.6) | |
| M4Eo+ | 20 | 2 | 18 | |
| M5 | 34 (18.6) | 9 (16.4) | 25 (19.5) | |
| M6 | 3 (1.6) | 3 (5.5) | 0 (0) | |
| M7 | 12 (6.6) | 9 (16.4) | 3 (2.3) | |
| Unclassified | 7 (3.8) | 4 (7.3) | 3 (2.3) |
| AML . | All patients . | Assay, unsuccessful . | Assay, successful . | P . |
|---|---|---|---|---|
| Patients, no. | 183 | 55 | 128 | |
| Age, median (P25-P75), y | 6.9 (2.4-11.8) | 5.0 (1.8-10.3) | 7.5 (3.1-12.6) | .02 |
| WBC count, median (P25-P75), ×109/L | 23.5 (6.9-72.9) | 8.7 (3.8-39.2) | 28.3 (12.5-88.4) | < .001 |
| Sex, % M:F ratio | 55.2:44.8 | 56.4:43.6 | 54.6:45.4 | .83 |
| FAB distribution, no. (%) | < .001 | |||
| M0 | 8 (4.4) | 2 (3.6) | 6 (4.7) | |
| M1 | 22 (12.0) | 8 (14.5) | 14 (10.9) | |
| M2 | 43 (23.5) | 12 (21.8) | 31 (24.2) | |
| M3 | 7 (3.8) | 0 (0) | 7 (5.5) | |
| M4 | 47 (25.7) | 8 (14.5) | 39 (30.6) | |
| M4Eo+ | 20 | 2 | 18 | |
| M5 | 34 (18.6) | 9 (16.4) | 25 (19.5) | |
| M6 | 3 (1.6) | 3 (5.5) | 0 (0) | |
| M7 | 12 (6.6) | 9 (16.4) | 3 (2.3) | |
| Unclassified | 7 (3.8) | 4 (7.3) | 3 (2.3) |
The samples received were for in vitro cellular drug resistance testing. The P values represent the statistical differences between patients with and without a successful drug resistance assay. P25 indicates the 25th percentile; P75, the 75th percentile; y, years.